An Open-label, Phase 1 Dose Escalation and Phase 2 Dose Expansion Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of SMP-3124LP in Adults With Advanced Solid Tumors.

This article provides information about a newly launched clinical trial, NCT06526819, conducted by Sumitomo Pharma America, Inc. The trial aims to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of SMP-3124LP in adults with advanced solid tumors. The study will determine the recommended phase 2 dose, evaluate adverse events, and measure the objective response rate. The trial is not yet recruiting and is expected to be completed by May 2029. The eligibility criteria include specific types of cancer, disease progression on standard therapy, and no alternative treatment options. The trial is open to all genders and individuals aged 18 years and above. Contact information is provided for further inquiries. [Extracted from the article]